These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9366927)

  • 1. Pancreas transplantation with ATG vs OKT3.
    Rosenberg L
    Transplant Proc; 1997 Nov; 29(7A):35S-36S. PubMed ID: 9366927
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody induction therapy in pancreas transplantation.
    Gruessner RW
    Transplant Proc; 1998 Jun; 30(4):1556-9. PubMed ID: 9636632
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
    Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
    Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
    [No Abstract]   [Full Text] [Related]  

  • 4. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
    Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP
    Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 6. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute pulmonary insufficiency due to OKT3 therapy.
    Büsing M; Mellert J; Greger B; Hopt UT
    Transplant Proc; 1990 Aug; 22(4):1779-81. PubMed ID: 2117808
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of immunosuppressive treatment for recurrent or refractory pancreas allograft rejection: correlation with histologic grade.
    Papadimitriou JC; Wiland A; Drachenberg CB; Klassen DK; Bartlett ST
    Transplant Proc; 1998 Dec; 30(8):3945. PubMed ID: 9865254
    [No Abstract]   [Full Text] [Related]  

  • 10. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
    Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
    Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
    Desai DM; Scandling JD; Knoppel C; Dafoe DC; Alfrey EJ
    Transplant Proc; 1998 Jun; 30(4):1552-4. PubMed ID: 9636630
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 14. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
    Woodle ES; Bluestone JA; Zivin RA; Jolliffe LK; Auger J; Xu D; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1369-70. PubMed ID: 9636555
    [No Abstract]   [Full Text] [Related]  

  • 15. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 17. Thymoglobulin induction decreases rejection in solitary pancreas transplantation.
    Stegall MD; Kim DY; Prieto M; Cohen AJ; Griffin MD; Schwab TR; Nyberg SL; Velosa JA; Gloor JM; Innocenti F; Bohorquez H; Dean PG; Carpenter HA; Leontovich ON; Sterioff S; Larson TS
    Transplantation; 2001 Nov; 72(10):1671-5. PubMed ID: 11726830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nursing implications of immunosuppression in transplantation.
    Shaefer M; Williams L
    Nurs Clin North Am; 1991 Jun; 26(2):291-314. PubMed ID: 1904575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.